ABCL250417P5000
- 2.49
- 0.000.00%
AbCellera Biologics Newsroom
Leerink Partners Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $5
Leerink Partners Remains a Buy on AbCellera Biologics (ABCL)
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $5
AbCellera Biologics Analyst Ratings
Keybanc Maintains Overweight on AbCellera Biologics, Raises Price Target to $5
Bloom Burton Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $9
Analysts Have Conflicting Sentiments on These Healthcare Companies: Castle Biosciences (CSTL), AbCellera Biologics (ABCL) and Apellis Pharmaceuticals (APLS)
Benchmark Co. Maintains AbCellera Biologics(ABCL.US) With Hold Rating
AbCellera Biologics Analyst Ratings
Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $10
TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL)
AbCellera Biologics Analyst Ratings
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $4
KeyBanc Cuts Price Target on AbCellera Biologics to $4 From $5, Keeps Overweight Rating
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating
Bloom Burton Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $9
A Quick Look at Today's Ratings for AbCellera Biologics(ABCL.US), With a Forecast Between $7 to $12
AbCellera Biologics Analyst Ratings
Benchmark Co. Maintains AbCellera Biologics(ABCL.US) With Hold Rating